Intermediate and high grade malignant non-Hodgkin's lymphomas

preliminary results using a new combination regimen (EVE-COPEM)

C. Battista, N. Panza, B. Chiurazzi, G. Iodice, G. Esposito, E. Cocorocchio, N. Bevilacqua, G. Pacilio

Research output: Contribution to journalArticle

Abstract

Between 1988 and 1992, 60 patients with intermediate and high-grade non-Hodgkin's lymphomas (NHL) were treated with a new multidrug combination chemotherapy including 4-epidoxorubicin (25 mg/m2), etoposide (60 mg/m2), cyclophosphamide (400 mg/m2), administered intravenously (iv) on the 1st, 2nd and 3rd day every 4 weeks, prednisone (40 mg/m2) orally for 6 days every 4 weeks, vincristine (1 mg/m2) iv and methotrexate (400 mg/m2) iv on the 8th day every 4 weeks, vindesine (2.5 mg/m2) and cytarabin (200 mg/m2) on the 15th day every 4 weeks. Patients achieving apparent complete remission (CR) or good partial response (PR) after the 1st cycle of therapy were submitted to three other cycles of the same therapy. Patients failing to respond to the 1st cycle or whose disease progressed despite therapy, were treated with an alternative 2nd line therapy. Seventeen patients (28%) had stage II-II E, 15 (25%) stage III and 28 (47%) stage IV disease. Tumoral mass > 10 cm was found in 28 cases, the presence of extranodal sites (ES) in 32 cases, serum lactate dehydrogenase (LDH) > 240 IU/I in 34 cases, performance status (PS) ≥2 in 12 cases. CR was obtained in 46 (76.4%) out of the 60 patients. Relapse-free survival (RFS) was 82, 64 and 61% with a median follow-up of 12, 24 and 36 months respectively. No relapse occurred later than 26 months after achievement with CR thus far. Overall survival (OS) was 77% at 12 months and calculated to be 62% and 59% at 24 and 36 months, respectively. Two patients died as a result of the treatment. Reversible mielosuppression was the main toxic effect. One hundred and ten out of the 221 cycles of chemotherapy were delayed because of therapy toxicity. Negative prognostic factors on the RFS and OS were the presence of an advanced stage of disease, a mass larger than 10 cm, the presence of ES, the elevated LDH, the PS ≥ 2, the delay of therapy. In conclusion, results obtained using our protocol overlap those from other third generation regimens. Toxicity was also similar. The influence of clinical conditions such as stage of disease, the presence of ES, high LDH level and tumoral mass > 10 cm on the RFS and OS were significant. Principal variables influencing prognosis must be unified to compare results of similar treatments from different institutions.

Original languageEnglish
Pages (from-to)145-154
Number of pages10
JournalBiomedicine and Pharmacotherapy
Volume47
Issue number4
DOIs
Publication statusPublished - 1993

Fingerprint

Non-Hodgkin's Lymphoma
Survival
L-Lactate Dehydrogenase
Recurrence
Therapeutics
Vindesine
Epirubicin
Poisons
Vincristine
Etoposide
Prednisone
Combination Drug Therapy
Methotrexate
Cyclophosphamide
Drug Therapy
Serum

Keywords

  • chemotherapy
  • high-grade NHL
  • intermediate NHL
  • non-Hodgkin's lymphomas
  • prognostic factors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Intermediate and high grade malignant non-Hodgkin's lymphomas : preliminary results using a new combination regimen (EVE-COPEM). / Battista, C.; Panza, N.; Chiurazzi, B.; Iodice, G.; Esposito, G.; Cocorocchio, E.; Bevilacqua, N.; Pacilio, G.

In: Biomedicine and Pharmacotherapy, Vol. 47, No. 4, 1993, p. 145-154.

Research output: Contribution to journalArticle

Battista, C. ; Panza, N. ; Chiurazzi, B. ; Iodice, G. ; Esposito, G. ; Cocorocchio, E. ; Bevilacqua, N. ; Pacilio, G. / Intermediate and high grade malignant non-Hodgkin's lymphomas : preliminary results using a new combination regimen (EVE-COPEM). In: Biomedicine and Pharmacotherapy. 1993 ; Vol. 47, No. 4. pp. 145-154.
@article{df38853d1e9b408391909679bff93cfe,
title = "Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM)",
abstract = "Between 1988 and 1992, 60 patients with intermediate and high-grade non-Hodgkin's lymphomas (NHL) were treated with a new multidrug combination chemotherapy including 4-epidoxorubicin (25 mg/m2), etoposide (60 mg/m2), cyclophosphamide (400 mg/m2), administered intravenously (iv) on the 1st, 2nd and 3rd day every 4 weeks, prednisone (40 mg/m2) orally for 6 days every 4 weeks, vincristine (1 mg/m2) iv and methotrexate (400 mg/m2) iv on the 8th day every 4 weeks, vindesine (2.5 mg/m2) and cytarabin (200 mg/m2) on the 15th day every 4 weeks. Patients achieving apparent complete remission (CR) or good partial response (PR) after the 1st cycle of therapy were submitted to three other cycles of the same therapy. Patients failing to respond to the 1st cycle or whose disease progressed despite therapy, were treated with an alternative 2nd line therapy. Seventeen patients (28{\%}) had stage II-II E, 15 (25{\%}) stage III and 28 (47{\%}) stage IV disease. Tumoral mass > 10 cm was found in 28 cases, the presence of extranodal sites (ES) in 32 cases, serum lactate dehydrogenase (LDH) > 240 IU/I in 34 cases, performance status (PS) ≥2 in 12 cases. CR was obtained in 46 (76.4{\%}) out of the 60 patients. Relapse-free survival (RFS) was 82, 64 and 61{\%} with a median follow-up of 12, 24 and 36 months respectively. No relapse occurred later than 26 months after achievement with CR thus far. Overall survival (OS) was 77{\%} at 12 months and calculated to be 62{\%} and 59{\%} at 24 and 36 months, respectively. Two patients died as a result of the treatment. Reversible mielosuppression was the main toxic effect. One hundred and ten out of the 221 cycles of chemotherapy were delayed because of therapy toxicity. Negative prognostic factors on the RFS and OS were the presence of an advanced stage of disease, a mass larger than 10 cm, the presence of ES, the elevated LDH, the PS ≥ 2, the delay of therapy. In conclusion, results obtained using our protocol overlap those from other third generation regimens. Toxicity was also similar. The influence of clinical conditions such as stage of disease, the presence of ES, high LDH level and tumoral mass > 10 cm on the RFS and OS were significant. Principal variables influencing prognosis must be unified to compare results of similar treatments from different institutions.",
keywords = "chemotherapy, high-grade NHL, intermediate NHL, non-Hodgkin's lymphomas, prognostic factors",
author = "C. Battista and N. Panza and B. Chiurazzi and G. Iodice and G. Esposito and E. Cocorocchio and N. Bevilacqua and G. Pacilio",
year = "1993",
doi = "10.1016/0753-3322(93)90005-6",
language = "English",
volume = "47",
pages = "145--154",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "4",

}

TY - JOUR

T1 - Intermediate and high grade malignant non-Hodgkin's lymphomas

T2 - preliminary results using a new combination regimen (EVE-COPEM)

AU - Battista, C.

AU - Panza, N.

AU - Chiurazzi, B.

AU - Iodice, G.

AU - Esposito, G.

AU - Cocorocchio, E.

AU - Bevilacqua, N.

AU - Pacilio, G.

PY - 1993

Y1 - 1993

N2 - Between 1988 and 1992, 60 patients with intermediate and high-grade non-Hodgkin's lymphomas (NHL) were treated with a new multidrug combination chemotherapy including 4-epidoxorubicin (25 mg/m2), etoposide (60 mg/m2), cyclophosphamide (400 mg/m2), administered intravenously (iv) on the 1st, 2nd and 3rd day every 4 weeks, prednisone (40 mg/m2) orally for 6 days every 4 weeks, vincristine (1 mg/m2) iv and methotrexate (400 mg/m2) iv on the 8th day every 4 weeks, vindesine (2.5 mg/m2) and cytarabin (200 mg/m2) on the 15th day every 4 weeks. Patients achieving apparent complete remission (CR) or good partial response (PR) after the 1st cycle of therapy were submitted to three other cycles of the same therapy. Patients failing to respond to the 1st cycle or whose disease progressed despite therapy, were treated with an alternative 2nd line therapy. Seventeen patients (28%) had stage II-II E, 15 (25%) stage III and 28 (47%) stage IV disease. Tumoral mass > 10 cm was found in 28 cases, the presence of extranodal sites (ES) in 32 cases, serum lactate dehydrogenase (LDH) > 240 IU/I in 34 cases, performance status (PS) ≥2 in 12 cases. CR was obtained in 46 (76.4%) out of the 60 patients. Relapse-free survival (RFS) was 82, 64 and 61% with a median follow-up of 12, 24 and 36 months respectively. No relapse occurred later than 26 months after achievement with CR thus far. Overall survival (OS) was 77% at 12 months and calculated to be 62% and 59% at 24 and 36 months, respectively. Two patients died as a result of the treatment. Reversible mielosuppression was the main toxic effect. One hundred and ten out of the 221 cycles of chemotherapy were delayed because of therapy toxicity. Negative prognostic factors on the RFS and OS were the presence of an advanced stage of disease, a mass larger than 10 cm, the presence of ES, the elevated LDH, the PS ≥ 2, the delay of therapy. In conclusion, results obtained using our protocol overlap those from other third generation regimens. Toxicity was also similar. The influence of clinical conditions such as stage of disease, the presence of ES, high LDH level and tumoral mass > 10 cm on the RFS and OS were significant. Principal variables influencing prognosis must be unified to compare results of similar treatments from different institutions.

AB - Between 1988 and 1992, 60 patients with intermediate and high-grade non-Hodgkin's lymphomas (NHL) were treated with a new multidrug combination chemotherapy including 4-epidoxorubicin (25 mg/m2), etoposide (60 mg/m2), cyclophosphamide (400 mg/m2), administered intravenously (iv) on the 1st, 2nd and 3rd day every 4 weeks, prednisone (40 mg/m2) orally for 6 days every 4 weeks, vincristine (1 mg/m2) iv and methotrexate (400 mg/m2) iv on the 8th day every 4 weeks, vindesine (2.5 mg/m2) and cytarabin (200 mg/m2) on the 15th day every 4 weeks. Patients achieving apparent complete remission (CR) or good partial response (PR) after the 1st cycle of therapy were submitted to three other cycles of the same therapy. Patients failing to respond to the 1st cycle or whose disease progressed despite therapy, were treated with an alternative 2nd line therapy. Seventeen patients (28%) had stage II-II E, 15 (25%) stage III and 28 (47%) stage IV disease. Tumoral mass > 10 cm was found in 28 cases, the presence of extranodal sites (ES) in 32 cases, serum lactate dehydrogenase (LDH) > 240 IU/I in 34 cases, performance status (PS) ≥2 in 12 cases. CR was obtained in 46 (76.4%) out of the 60 patients. Relapse-free survival (RFS) was 82, 64 and 61% with a median follow-up of 12, 24 and 36 months respectively. No relapse occurred later than 26 months after achievement with CR thus far. Overall survival (OS) was 77% at 12 months and calculated to be 62% and 59% at 24 and 36 months, respectively. Two patients died as a result of the treatment. Reversible mielosuppression was the main toxic effect. One hundred and ten out of the 221 cycles of chemotherapy were delayed because of therapy toxicity. Negative prognostic factors on the RFS and OS were the presence of an advanced stage of disease, a mass larger than 10 cm, the presence of ES, the elevated LDH, the PS ≥ 2, the delay of therapy. In conclusion, results obtained using our protocol overlap those from other third generation regimens. Toxicity was also similar. The influence of clinical conditions such as stage of disease, the presence of ES, high LDH level and tumoral mass > 10 cm on the RFS and OS were significant. Principal variables influencing prognosis must be unified to compare results of similar treatments from different institutions.

KW - chemotherapy

KW - high-grade NHL

KW - intermediate NHL

KW - non-Hodgkin's lymphomas

KW - prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0027228009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027228009&partnerID=8YFLogxK

U2 - 10.1016/0753-3322(93)90005-6

DO - 10.1016/0753-3322(93)90005-6

M3 - Article

VL - 47

SP - 145

EP - 154

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 4

ER -